Prevalence of use of hormone replacement therapy in women participating in a breast cancer screening program

被引:7
作者
Martinez-Pino, Isabel [1 ,2 ]
Puig, Teresa [1 ,5 ]
Jesus Quintana, Maria [1 ,3 ]
Sola, Judit [4 ]
Bonfill, Xavier [1 ,3 ,4 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Serv Epidemiol Clin & Salud Publ, E-08193 Barcelona, Spain
[2] Univ Autonoma Barcelona, Dept Pediat Obstet & Ginecol & Med Prevent, Programa Doctorado Salud Pnbl & Metodol Invest Bi, E-08193 Barcelona, Spain
[3] CIBERESP, Barcelona, Spain
[4] Ctr Cochrane Iberoamer, Barcelona, Spain
[5] Red Temat Invest Clin & Basica Insuficiencia Card, Madrid, Spain
来源
MEDICINA CLINICA | 2010年 / 134卷 / 10期
关键词
Hormone replacement therapy; Prevalence; Mass screening; Breast neoplasm;
D O I
10.1016/j.medcli.2009.10.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: The purpose of the study was to determine the prevalence and type of hormone replacement therapy (HRT) in participants in a breast cancer screening program (BCSP) in Barcelona. Patients and Method: Prevalence of use of HRT was obtained through a survey. Information about type of HRT, gynecological history and socioeconomic and educational level was collected. Prevalence was calculated with its corresponding 95% confidence interval. Results: From May 2001 to June 2005 there were 21835 participants in the BCSP with a mean age of 57,6 years. Most of the participants were postmenopausal (86,7%). Confirmed prevalence of use of HRT was 5,2%(CI95% 5,3-6,0) with a greater use among women aged 55 to 59 years. The most frequent types of HRT were tibolone (39,5%) followed by combined estrogens plus progestin (30,4%). Higher education was associated with a higher use of HRT. Neither the use or the type of HRT influenced the results of the screening program. Conclusions: Prevalence of use of HRT was 5,2% in this study. The most frequently used agents were tibolone and combined estrogens plus progestin. (c) 2009 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:439 / 442
页数:4
相关论文
共 50 条
  • [21] Hormone replacement therapy and risk of breast cancer
    Ortmann, O
    Schulz, KD
    Diedrich, K
    GYNAKOLOGE, 2000, 33 (06): : 402 - 407
  • [22] Risk of breast cancer with hormone replacement therapy
    Michels, KB
    MIDLIFE HEALTH - CURRENT CONCEPTS AND CHALLENGES FOR THE FUTURE, 2002, 1229 : 135 - 141
  • [23] Hormone replacement therapy and risk of breast cancer: the role of progestins
    Stahlberg, C
    Pedersen, AT
    Lynge, E
    Ottesen, B
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2003, 82 (04) : 335 - 344
  • [24] Hormone Replacement Therapy after Breast Cancer?
    Harold J. Burstein
    Breast Cancer Research and Treatment, 2003, 81 (Suppl 1) : 99 - 101
  • [25] Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens
    Hofvind, Solveig
    Moller, Bjorn
    Thoresen, Steinar
    Ursin, Giske
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (12) : 3112 - 3117
  • [26] Hormone replacement therapy following breast cancer
    Kubista, E
    ONKOLOGIE, 1997, 20 (06): : 486 - 488
  • [27] Hormone replacement therapy and the risk of breast cancer
    Cuzick, Jack
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (16) : 2344 - 2349
  • [28] Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium
    Antoine, C.
    Ameye, L.
    Moreau, M.
    Paesmans, M.
    Rozenberg, S.
    CLIMACTERIC, 2011, 14 (04) : 464 - 471
  • [29] Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis
    Fletcher, AS
    Erbas, B
    Kavanagh, AM
    Hart, S
    Rodger, A
    Gertig, DM
    BREAST, 2005, 14 (03) : 192 - 200
  • [30] Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy
    Silverman, Barbara G.
    Siegelmann-Danieli, Nava
    Braunstein, Rony
    Kokia, Ehud S.
    CANCER EPIDEMIOLOGY, 2011, 35 (01) : 11 - 16